broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K51313569-001-07-8 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.849424 | 5.127908 | 0.094861 | 0.955728 | 0.576499 | null | palbociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O | Launched | true | ACH-000971 |
BRD-K51791723-003-01-7 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.127127 | 0.802691 | 0.685724 | 0.623698 | 0.156931 | 0.22617 | P276-00 | CDK inhibitor | CDK1, CDK4, CDK9 | null | null | CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000971 |
BRD-K51967704-001-03-6 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.19931 | 1.6026 | 0.799576 | 0.840538 | 1.489876 | 2.046247 | BIIB021 | HSP inhibitor | HSP90AA1 | null | null | COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C | Phase 2 | true | ACH-000971 |
BRD-K52313696-001-12-3 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.10565 | 2.861568 | 0.434213 | 0.965038 | 7.90259 | 8.585963 | tacedinaline | HDAC inhibitor | HDAC1 | null | null | CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N | Phase 3 | true | ACH-000971 |
BRD-K54256913-001-08-7 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.759236 | -6.970894 | -0.054878 | 0.94841 | 0.00488 | null | MK-1775 | WEE1 kinase inhibitor | WEE1 | null | null | CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1 | Phase 2 | true | ACH-000971 |
BRD-K54955827-001-02-2 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.595919 | 0.37734 | -0.026698 | 0.816624 | 0.145287 | null | niraparib | PARP inhibitor | PARP1 | oncology | primary peritoneal cancer (PPC) | NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1 | Launched | true | ACH-000971 |
BRD-K54997624-001-06-0 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.901562 | -0.274104 | 0.008776 | 0.977988 | 0.000469 | null | alpelisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | null | null | Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F | Phase 3 | true | ACH-000971 |
BRD-K55187425-236-05-2 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.261199 | 4.30115 | 0.663968 | 0.596392 | 0.049834 | 0.059175 | rigosertib | cell cycle inhibitor, PLK inhibitor | PLK1 | null | null | COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1 | Phase 3 | true | ACH-000971 |
BRD-K56981171-001-02-8 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.797971 | -0.070819 | -0.081796 | 0.836017 | 84,514,511.467466 | null | brigatinib | ALK tyrosine kinase receptor inhibitor, EGFR inhibitor | ALK, EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1 | Launched | true | ACH-000971 |
BRD-K57169635-001-04-5 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 1.039076 | 4.578147 | -0.096842 | 1 | 0.021472 | null | dacomitinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1 | Phase 3 | true | ACH-000971 |
BRD-K58435339-001-03-0 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.413771 | 0.415479 | 0.264613 | 0.694965 | 0.060337 | 4.147476 | AT13387 | HSP antagonist | HSP90AA1 | null | null | CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O | Phase 2 | true | ACH-000971 |
BRD-K58529924-001-01-5 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.814084 | 0.13473 | 0.016473 | 0.903356 | 0.045001 | null | ONC201 | AKT inhibitor, MAP kinase inhibitor | TNFSF10 | null | null | Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O | Phase 2 | true | ACH-000971 |
BRD-K58550667-001-08-7 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.161138 | 3.33204 | 0.740484 | 0.658048 | 0.011959 | 0.01344 | FK-866 | niacinamide phosphoribosyltransferase inhibitor | NAMPT | null | null | O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1 | Phase 2 | true | ACH-000971 |
BRD-K59317601-001-05-5 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.422316 | 1.868278 | 0.636353 | 0.826636 | 0.544725 | 1.475719 | MLN0128 | mTOR inhibitor | MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12 | Phase 2 | true | ACH-000971 |
BRD-K59369769-001-22-9 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.761589 | 0.15723 | -0.055828 | 0.922328 | 9.861195 | null | tozasertib | Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor | AURKA, AURKB, AURKC, LCK | null | null | CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1 | Phase 2 | true | ACH-000971 |
BRD-K60866521-001-07-1 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.78109 | -0.441741 | -0.125125 | 0.844659 | 1.153256 | null | idelalisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1 | Launched | true | ACH-000971 |
BRD-K60997853-001-02-3 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.016458 | 1.54073 | 0.582033 | 0.865483 | 2.901485 | 2.965223 | PHA-848125 | CDK inhibitor, growth factor receptor inhibitor | CDK2, CDK4, CDK7, NTRK1 | null | null | CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21 | Phase 2 | true | ACH-000971 |
BRD-K61192372-001-08-9 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.67874 | -0.694378 | 0.119572 | 0.752202 | 1.525847 | null | capecitabine | DNA synthesis inhibitor, thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O | Launched | true | ACH-000971 |
BRD-K62008436-001-23-9 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.172363 | 5.653069 | 0.86882 | 0.642018 | 0.009392 | 0.010121 | paclitaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1 | oncology | ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC) | CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 | Launched | true | ACH-000971 |
BRD-K62196610-001-01-6 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.500834 | 0.420581 | 0.335992 | 0.828533 | 0.589593 | null | AVN-944 | inosine monophosphate dehydrogenase inhibitor | IMPDH1, IMPDH2 | null | null | CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1 | Phase 2 | true | ACH-000971 |
BRD-K62200014-003-10-5 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.833785 | -0.034148 | -0.014053 | 0.9143 | 0.487622 | null | anagrelide | phosphodiesterase inhibitor | PDE3A | hematology, hematologic malignancy | thrombocythemia, myeloproliferative neoplasms | Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl | Launched | true | ACH-000971 |
BRD-K62391742-001-09-7 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.899701 | -1.981977 | 0.150673 | 0.939587 | 0.210884 | null | venetoclax | BCL inhibitor | BCL2 | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 | Launched | true | ACH-000971 |
BRD-K62627508-001-01-5 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.33486 | 0.480464 | 0.524335 | 0.646129 | 0.053517 | 0.536847 | idasanutlin | MDM inhibitor | MDM2, TP53 | null | null | COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O | Phase 3 | true | ACH-000971 |
BRD-K63504947-001-14-7 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.826074 | -1.133939 | 0.044417 | 0.984206 | 0.000982 | null | semaxanib | VEGFR inhibitor | FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET | null | null | Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1 | Phase 3 | true | ACH-000971 |
BRD-K63712959-001-01-8 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.87677 | -1.254817 | 0.012031 | 0.968863 | 0.006823 | null | temoporfin | radical formation stimulant | null | oncology | head and neck squamous cell carcinoma (HNSCC) | Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2 | Launched | true | ACH-000971 |
BRD-K64052750-001-22-5 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.969957 | -0.701854 | -0.001428 | 0.981774 | 0.237807 | null | gefitinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1 | Launched | true | ACH-000971 |
BRD-K64881305-001-03-7 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.42261 | 3.005975 | 0.462328 | 0.509898 | 0.002635 | 0.004901 | ispinesib | kinesin inhibitor | KIF11 | null | null | CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1 | Phase 2 | true | ACH-000971 |
BRD-K66175015-001-12-4 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.178183 | 4.988065 | 0.524669 | 0.896389 | 2.943248 | 3.215109 | afatinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | oncology | non-small cell lung cancer (NSCLC) | CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1 | Launched | true | ACH-000971 |
BRD-K67844266-003-01-9 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.144952 | 1.434106 | 0.768176 | 0.544619 | 0.056896 | 0.072237 | pevonedistat | nedd activating enzyme inhibitor | NAE1, UBA3 | null | null | NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12 | Phase 2 | true | ACH-000971 |
BRD-K69694239-001-02-2 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.069771 | 1.939662 | 0.437796 | 0.731459 | 0.608522 | 0.65755 | bardoxolone-methyl | nuclear factor erythroid derived, like (NRF2) activator | PPARG, STAT3 | null | null | COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 | Phase 3 | true | ACH-000971 |
BRD-K69776681-001-03-8 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.17872 | 2.036067 | 0.577897 | 0.752378 | 0.536782 | 0.667021 | volasertib | PLK inhibitor | PLK1 | null | null | CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O | Phase 3 | true | ACH-000971 |
BRD-K70301465-001-05-9 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 1.136347 | -0.010204 | -0.001412 | 1 | 474,577,765.779738 | null | ibrutinib | Bruton's tyrosine kinase (BTK) inhibitor | BLK, BMX, BTK | hematologic malignancy | chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM) | Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C | Launched | true | ACH-000971 |
BRD-K70401845-001-15-7 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 1.112468 | -0.298057 | -0.021695 | 1 | 0.279303 | null | erlotinib | EGFR inhibitor | EGFR, NR1I2 | oncology | non-small cell lung cancer (NSCLC), pancreatic cancer | COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC | Launched | true | ACH-000971 |
BRD-K73838513-003-05-5 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.467591 | 1.354955 | 0.243718 | 0.837507 | 0.524177 | 3.949017 | cinacalcet | calcium channel activator | CASR | endocrinology, nephrology, oncology | hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia | C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12 | Launched | true | ACH-000971 |
BRD-K74514084-003-09-2 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.692014 | 4.391995 | 0.385135 | 0.874025 | 0.188837 | null | pazopanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3 | oncology | renal cell carcinoma (RCC), soft tissue sarcoma (STS) | CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1 | Launched | true | ACH-000971 |
BRD-K75009076-001-02-1 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | -0.343661 | 2.207406 | 0.472298 | 0.932018 | 7.379067 | 5.821936 | SCH-900776 | CHK inhibitor | CDK2, CHEK1 | null | null | Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1 | Phase 2 | true | ACH-000971 |
BRD-K76239644-001-02-6 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.872872 | -1.334644 | 0.087731 | 0.93419 | 0.09276 | null | BMS-690514 | EGFR inhibitor, VEGFR inhibitor | EGFR, ERBB2, FLT3, KDR | null | null | COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1 | Phase 2 | true | ACH-000971 |
BRD-K76674262-001-03-3 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.262394 | 1.308034 | 0.774154 | 0.576782 | 0.038061 | 0.067219 | homoharringtonine | protein synthesis inhibitor | RPL3 | hematologic malignancy | chronic myeloid leukemia (CML) | COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC | Launched | true | ACH-000971 |
BRD-K76908866-001-07-6 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.817252 | -0.518353 | 0.004993 | 0.975599 | 0.000575 | null | CP-724714 | EGFR inhibitor, protein tyrosine kinase inhibitor | ERBB2 | null | null | COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1 | Phase 2 | true | ACH-000971 |
BRD-K77625799-001-07-7 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.823927 | -7.919573 | 0.205278 | 0.888196 | 0.289458 | null | vandetanib | EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA | oncology | medullary thyroid cancer (MTC) | COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1 | Launched | true | ACH-000971 |
BRD-K78431006-001-15-1 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.799705 | 0.82514 | 0.121724 | 0.932219 | 0.404882 | null | crizotinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl | Launched | true | ACH-000971 |
BRD-K79254416-001-21-8 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.29254 | 0.331512 | 0.378038 | 0.633235 | 0.059717 | 0.848219 | decitabine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML) | Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1 | Launched | true | ACH-000971 |
BRD-K81016934-001-02-0 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 1.110775 | -0.289774 | -0.000856 | 1 | 0.012366 | null | INC-280 | c-Met inhibitor | MET | null | null | CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1 | Phase 2 | true | ACH-000971 |
BRD-K81418486-001-44-2 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.037818 | 1.574631 | 0.74715 | 0.826149 | 1.805037 | 1.897486 | vorinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9 | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1 | Launched | true | ACH-000971 |
BRD-K81473043-001-19-5 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.248877 | 3.372374 | 0.461468 | 0.89374 | 0.158804 | 0.194782 | tanespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 3 | true | ACH-000971 |
BRD-K82135108-001-04-3 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.494492 | 2.580227 | 0.472311 | 0.643156 | 0.007038 | 0.040391 | elesclomol | oxidative stress inducer | HSPA1A | null | null | CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1 | Phase 3 | true | ACH-000971 |
BRD-K82746043-001-19-3 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 38.562812 | 0.505927 | -0.012178 | 1 | 3,160,684.37301 | null | navitoclax | BCL inhibitor | BCL2, BCL2L1, BCL2L2 | null | null | CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 | Phase 2 | true | ACH-000971 |
BRD-K82818427-001-04-8 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.915589 | 0.431592 | -0.007413 | 0.974486 | 1.008709 | null | batimastat | matrix metalloprotease inhibitor | ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8 | null | null | CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO | Phase 3 | true | ACH-000971 |
BRD-K83029223-001-01-3 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.305604 | 3.944441 | 0.809683 | 0.521 | 0.000773 | 0.000983 | litronesib | kinesin-like spindle protein inhibitor | KIF11 | null | null | CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 | Phase 2 | true | ACH-000971 |
BRD-K83988098-001-02-0 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.603383 | -0.016385 | -0.087503 | 0.807548 | 0.000033 | null | alvespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 2 | true | ACH-000971 |
BRD-K85606544-001-09-1 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.616359 | -0.299194 | 0.050097 | 0.839737 | 0.021363 | null | neratinib | EGFR inhibitor | EGFR, ERBB2, KDR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 3 | true | ACH-000971 |
BRD-K86118762-001-01-8 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.81072 | -1.797377 | 0.066539 | 0.960686 | 0.00451 | null | linsitinib | IGF-1 inhibitor | IGF1R, INSR, INSRR | null | null | C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 | Phase 3 | true | ACH-000971 |
BRD-K86972824-001-01-4 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.866564 | -0.239352 | 0.024804 | 0.94074 | 0.027586 | null | oltipraz | nuclear factor erythroid derived, like (NRF2) activator | ANG | null | null | Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1 | Phase 3 | true | ACH-000971 |
BRD-K87737963-001-06-0 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.773877 | -0.069879 | -0.029463 | 0.874947 | 1.692883 | null | cyt387 | null | JAK1, JAK2, JAK3 | null | null | O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1 | Phase 3 | true | ACH-000971 |
BRD-K87782578-001-01-4 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.846409 | 0.051346 | -0.034374 | 0.917029 | 0.003329 | null | AVL-292 | Bruton's tyrosine kinase (BTK) inhibitor | BTK, YES1 | null | null | COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1 | Phase 2 | true | ACH-000971 |
BRD-K87909389-003-03-4 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.361501 | 1.967187 | 0.784674 | 0.639238 | 0.041553 | 0.0798 | alvocidib | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM | null | null | CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000971 |
BRD-K88510285-001-17-8 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.238499 | 0.916049 | 0.82829 | 0.632602 | 0.023278 | 0.047233 | bortezomib | NFkB pathway inhibitor, proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA | hematologic malignancy | multiple myeloma, mantle cell lymphoma (MCL) | CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O | Launched | true | ACH-000971 |
BRD-K89014967-001-04-3 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.010537 | 0.455592 | 0.436284 | 0.708096 | 1.035608 | 1.085173 | AS-703026 | MEK inhibitor | MAP2K1, MAP2K2 | null | null | OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F | Phase 2 | true | ACH-000971 |
BRD-K92441787-001-04-1 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.852822 | -2.236695 | 0.216693 | 0.888454 | 0.956377 | null | bexarotene | retinoid receptor agonist | RXRA, RXRB, RXRG | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C | Launched | true | ACH-000971 |
BRD-K92723993-001-17-4 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 6.996148 | 0.811165 | 0.065943 | 1 | 466.32497 | null | imatinib | Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET | hematologic malignancy, oncology | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST) | CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1 | Launched | true | ACH-000971 |
BRD-K95142244-001-01-5 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.691711 | 0.184711 | 0.009123 | 0.811649 | 0.005789 | null | talazoparib | PARP inhibitor | PARP2 | null | null | Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1 | Phase 3 | true | ACH-000971 |
BRD-K96123349-236-02-8 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 1.32831 | 0.188424 | 0.053815 | 1 | 2.811529 | null | brequinar | dihydroorotate dehydrogenase inhibitor | DHODH | null | null | Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F | Phase 2 | true | ACH-000971 |
BRD-K98572433-001-02-9 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 1.508582 | 1.123321 | 0.362172 | 1 | 0.291955 | null | AZD8931 | EGFR inhibitor | EGFR, ERBB2, ERBB3 | null | null | CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC | Phase 2 | true | ACH-000971 |
BRD-K99113996-001-02-0 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 1.376581 | 0.462808 | 0.201787 | 1 | 0.310932 | null | AZD2014 | mTOR inhibitor | MTOR | null | null | CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C | Phase 2 | true | ACH-000971 |
BRD-K99616396-001-05-1 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.756578 | -0.048106 | -0.08397 | 0.878455 | 0.073778 | null | motesanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT1, FLT4, KDR, KIT | null | null | CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12 | Phase 3 | true | ACH-000971 |
BRD-K99749624-001-07-0 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.630911 | 0.338477 | -0.066399 | 0.844575 | 0.244389 | null | linifanib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK | null | null | Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1 | Phase 3 | true | ACH-000971 |
BRD-M97302542-001-04-4 | ACH-000971 | HCT116_LARGE_INTESTINE | MTS010 | 1 | 0.796049 | 1.279625 | 0.175023 | 0.934034 | 0.439442 | null | dichloroacetate | pyruvate dehydrogenase kinase inhibitor | PDK1 | null | null | [Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl | Phase 3 | true | ACH-000971 |
BRD-A25234499-001-19-1 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 1.134862 | 0.06056 | -0.004 | 1 | 0.007639 | null | aminoglutethimide | glucocorticoid receptor antagonist | CYP11A1, CYP19A1 | endocrinology, oncology | Cushing's syndrome, breast cancer | CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1 | Launched | true | ACH-000972 |
BRD-A70858459-001-01-7 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.801481 | -0.015142 | -0.008739 | 0.883506 | 909,881,688.392315 | null | estramustine | DNA alkylating agent | ESR1, ESR2, MAP1A, MAP2 | oncology | prostate cancer | C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O | Launched | true | ACH-000972 |
BRD-A74914197-001-02-9 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.765338 | 2.900281 | 0.234185 | 0.844069 | 0.000989 | null | pralatrexate | dihydrofolate reductase inhibitor | DHFR, TYMS | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 | Launched | true | ACH-000972 |
BRD-K02113016-001-19-6 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 1.036606 | -0.110469 | -0.015019 | 1 | 0.237613 | null | olaparib | PARP inhibitor | PARP1, PARP2 | oncology | ovarian cancer | Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1 | Launched | true | ACH-000972 |
BRD-K02130563-001-11-4 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.085916 | 0.737353 | 0.770076 | 0.426243 | 0.020827 | 0.026895 | panobinostat | HDAC inhibitor | HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | multiple myeloma | Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1 | Launched | true | ACH-000972 |
BRD-K03390685-001-01-7 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.675284 | 7.450722 | 0.348701 | 0.787971 | 0.0177 | null | cobimetinib | MEK inhibitor | null | oncology | melanoma | OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1 | Launched | true | ACH-000972 |
BRD-K03406345-001-21-1 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.699971 | 3.003548 | 0.318365 | 0.946865 | 1.796457 | null | azacitidine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL) | Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000972 |
BRD-K03449891-001-08-6 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.874022 | -1.920906 | 0.009841 | 0.94896 | 0.017728 | null | foretinib | VEGFR inhibitor | FLT1, FLT4, KDR, MET | null | null | COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1 | Phase 2 | true | ACH-000972 |
BRD-K03765900-001-01-9 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | -1.390528 | 0.944936 | 0.232641 | 0.891477 | 20.123919 | 4.925373 | XL-647 | EGFR inhibitor, VEGFR inhibitor | EGFR, EPHB4, ERBB2, FLT4, KDR | null | null | COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1 | Phase 3 | true | ACH-000972 |
BRD-K05804044-001-18-5 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.575991 | 1.461592 | 0.413416 | 0.862452 | 0.432262 | null | AZ-628 | RAF inhibitor | BRAF, RAF1 | null | null | Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1 | Preclinical | true | ACH-000972 |
BRD-K06814349-304-02-7 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.45972 | 1.005239 | 0.751763 | 0.798681 | 0.275507 | 3.375335 | fosbretabulin | tubulin polymerization inhibitor, VE-cadherin antagonist | CDH5 | null | null | COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O | Phase 3 | true | ACH-000972 |
BRD-K08109215-001-06-4 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.417641 | 2.77057 | 0.572916 | 0.904426 | 2.042783 | 3.916846 | I-BET-762 | bromodomain inhibitor | BRD2, BRD3, BRD4 | null | null | CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 | Phase 2 | true | ACH-000972 |
BRD-K08542803-001-02-3 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.04576 | 2.650135 | 0.831455 | 0.666811 | 0.337596 | 0.350047 | gambogic-acid | caspase activator | BCL2 | null | null | CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C | Phase 2 | true | ACH-000972 |
BRD-K08547377-001-04-4 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.08235 | 2.878302 | 0.563518 | 0.915851 | 4.223123 | 4.495603 | irinotecan | topoisomerase inhibitor | TOP1, TOP1MT | oncology | colorectal cancer | CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12 | Launched | true | ACH-000972 |
BRD-K08703257-001-13-9 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.982905 | 0.055256 | -0.013928 | 0.989897 | 0.000096 | null | 3-amino-benzamide | PARP inhibitor | PARP1 | null | null | NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1 | Phase 2 | true | ACH-000972 |
BRD-K08799216-001-05-3 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.071675 | 1.123889 | 0.539727 | 0.862142 | 2.879504 | 3.30451 | pelitinib | EGFR inhibitor | EGFR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 2 | true | ACH-000972 |
BRD-K09951645-001-11-8 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.378231 | 3.553334 | 0.525451 | 0.920249 | 2.889906 | 4.30051 | dabrafenib | RAF inhibitor | BRAF, LIMK1, NEK11, RAF1, SIK1 | oncology | melanoma | CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F | Launched | true | ACH-000972 |
BRD-K11630072-001-13-2 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.740903 | 4.56076 | 0.467895 | 0.918803 | 0.477735 | null | carmofur | thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O | Launched | true | ACH-000972 |
BRD-K12184916-001-19-6 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.471196 | 0.811905 | 0.353578 | 0.524187 | 0.000746 | 0.025089 | NVP-BEZ235 | mTOR inhibitor, PI3K inhibitor | ATR, MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1 | Phase 2 | true | ACH-000972 |
BRD-K12343256-001-14-7 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.633723 | 3.219163 | 0.581373 | 0.732957 | 0.008456 | null | trametinib | MEK inhibitor | MAP2K1, MAP2K2 | oncology | melanoma | CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O | Launched | true | ACH-000972 |
BRD-K13049116-001-04-0 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 1.010836 | -0.012535 | -0.007211 | 1 | 0.852981 | null | BMS-754807 | IGF-1 inhibitor | AKT1, IGF1R | null | null | C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1 | Phase 2 | true | ACH-000972 |
BRD-K13390322-001-06-3 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.13701 | 3.794931 | 0.852541 | 0.711885 | 0.391654 | 0.42614 | AT-7519 | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK9 | null | null | Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1 | Phase 2 | true | ACH-000972 |
BRD-K13514097-001-04-6 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.788396 | -0.074281 | -0.042544 | 0.896367 | 0.044705 | null | everolimus | mTOR inhibitor | MTOR | oncology, neurology/psychiatry, genetics, urology | breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO | Launched | true | ACH-000972 |
BRD-K13662825-001-07-5 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.090872 | 2.608108 | 0.908445 | 0.527232 | 0.016105 | 0.017392 | dinaciclib | CDK inhibitor | CDK1, CDK2, CDK5, CDK9 | null | null | CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO | Phase 3 | true | ACH-000972 |
BRD-K14109347-001-03-4 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.5601 | 0.863295 | 0.349362 | 0.923778 | 2.531937 | null | LY2603618 | CHK inhibitor | CHEK1 | null | null | Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1 | Phase 2 | true | ACH-000972 |
BRD-K15179879-001-03-2 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.116272 | 12.48415 | 0.781252 | 0.602823 | 0.127581 | 0.130314 | carfilzomib | proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9 | hematologic malignancy | multiple myeloma | CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1 | Launched | true | ACH-000972 |
BRD-K15600710-066-05-8 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.183837 | 5.7089 | 0.771098 | 0.740276 | 0.447539 | 0.484953 | obatoclax | BCL inhibitor | BCL2 | null | null | COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 | Phase 3 | true | ACH-000972 |
BRD-K16730910-001-10-7 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.726811 | -0.365205 | -0.188787 | 0.884028 | 0.027639 | null | regorafenib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK | oncology | colorectal cancer, gastrointestinal stromal tumors (GIST) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1 | Launched | true | ACH-000972 |
BRD-K17555800-003-02-3 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 1.109161 | 1.591707 | 0.105188 | 1 | 0.032408 | null | talmapimod | p38 MAPK inhibitor | MAPK11, MAPK14 | null | null | C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C | Phase 2 | true | ACH-000972 |
BRD-K17610631-001-03-3 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.379868 | 2.726803 | 0.661451 | 0.760941 | 0.229837 | 0.38774 | indisulam | CDK inhibitor | CA1, CA12, CA14, CA2, CA6, CA7, CA9 | null | null | NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12 | Phase 2 | true | ACH-000972 |
BRD-K17743125-001-08-4 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | -0.095617 | 1.518881 | 0.734967 | 0.863988 | 3.363421 | 2.997375 | belinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1 | Launched | true | ACH-000972 |
BRD-K18961567-001-01-1 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.63855 | 3.228869 | 0.419104 | 0.948491 | 2.517328 | null | LY2801653 | MET inhibitor | MET | null | null | Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1 | Phase 2 | true | ACH-000972 |
BRD-K19540840-001-09-4 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.509997 | 1.299476 | 0.436392 | 0.821323 | 0.292693 | null | saracatinib | src inhibitor | ABL1, LCK, SRC, YES1 | null | null | CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1 | Phase 2/Phase 3 | true | ACH-000972 |
Subsets and Splits
No saved queries yet
Save your SQL queries to embed, download, and access them later. Queries will appear here once saved.